SEC Filings
Ultragenyx To Cut About 20% Of Staff, Wind Down GTX-102 Studies And Drop UX701
The rare-disease drugmaker reaffirmed 2027 profitability and said the cuts should lower 2027 R&D spending by at least 50% versus 2025.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The rare-disease drugmaker reaffirmed 2027 profitability and said the cuts should lower 2027 R&D spending by at least 50% versus 2025.
Earnings
Revenue rose 7% to $10 billion, but adjusted EBITDA fell to $116 million, a 1.2% margin, from $413 million a year earlier.
Earnings
The social media software maker lifted its year-end margin outlook to about 18% and began repurchasing stock under a $50 million program.
Earnings
The lidar maker guides to $61 million to $64 million in fourth-quarter revenue and holds $421 million in cash and short-term investments.
Earnings
The chipmaker guides fourth-quarter revenue to $16.0 million and expects AI infrastructure to top 40% of sales by year-end.
SEC Filings
Cash of $252.0 million is meant to last into the second half of 2029, and the dry eye trial's topline results are due around year-end.
Deals
Revenue rose 64% to $340.5 million, and the drugmaker held its $1.1 billion to $1.2 billion 2026 revenue forecast.
SEC Filings
The precious-metals asset manager will pay on December 1 to holders of record on November 16, with currency set by residency.
Earnings
The diagnostics maker targets over $80 million in 2027 savings and cut the top of its 2026 revenue and EPS ranges.
Earnings
The AI-connectivity chipmaker guided fourth-quarter revenue to $730 million to $750 million after record third-quarter sales.
Deals
The company also skipped guidance and its earnings call because of the pending Proofpoint acquisition.
SEC Filings
The trucker will meet investors at two November conferences, with a webcast possible only for the Nashville event.